Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.125p +2.08% 6.125p 6.00p 6.25p 6.125p 5.875p 6.00p 547,665 13:09:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 4.58

N4 Pharma Share Discussion Threads

Showing 626 to 649 of 650 messages
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
DateSubjectAuthorDiscuss
17/10/2017
16:30
Not exactly rocketing jakleeds, will be back down to 6p tomorrow knowing the mm's
whl2
17/10/2017
15:54
N4 Pharma have joined the line up for our next London seminar on the 8th November: hTTps://www.sharesoc.org/events/sharesoc-growth-company-seminar-london-8-november-2017/ Join us for presentations and a chance to ask questions to management.
sharesoc
17/10/2017
13:12
Nice reversal - chart looks ripe for a massive breakout imo
jakleeds
10/10/2017
23:27
Published patent application referred to in the RNS is here for anyone who is interested: https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20171005&DB=&locale=en_EP&CC=WO&NR=2017168174A1&KC=A1&ND=4
timbo003
10/10/2017
15:18
Idiots selling at a loss rather than wait a few months for transformational patient studies to begin?! No wonder 80% of AIM punters lose money
trotterstrading
10/10/2017
08:07
Nice update. Massive potential here, not without risk of course.
jakleeds
10/10/2017
07:53
Having only looked briefly at N4P before, I wasn't aware of the market research they quote today. Those percentages of clinicians potentially prepared to switch to N4P's formulation, particularly in the US, are higher than I would have expected. Very interesting, if they can get this to market.
photon
10/10/2017
07:15
Nigel Theobald, CEO of N4 Pharma, commented: "The publication of the Patent Application marks another important step in our lead product sildenafil as we head towards our initial human pilot clinical trials within the next few months. With the Patent Application now formally published, we can talk more freely with investors and other interested parties about what our reformulated sildenafil will hope to achieve in terms of its pharmacokinetic properties and where it might sit amongst competitors in this highly lucrative market."
parob
06/10/2017
09:36
Yep. Some interest here today ...
jakleeds
06/10/2017
09:14
V shaped bowl formation. BOWL.
escapetohome
06/10/2017
09:10
Chart curving nicely upwards here. Risky, but could be an absolute cracker imo
jakleeds
25/9/2017
20:10
sufficient cash for admin expenses only looking at them. not getting any product to market. cash call soon!!
backtogo
25/9/2017
20:04
LOLthat's why nobody takes any notice of you
backtogo
25/9/2017
20:01
Rule 1 on the boards TT......never engage with a bell end!
flashheart
25/9/2017
19:33
Read the results Backtogo ffs! Sufficient cash for 2017 and 2018!
trotterstrading
25/9/2017
10:51
Burnt 200k in 2 month?Fair to assume that cash burn was higher immediately after listing. But even at 100k + the current cash will be gone within a year.Better get a product to market fast. Or suffer dilution.
backtogo
15/9/2017
09:57
I can only buy 5000 shares online but I can sell 150000. Perhaps there is something happening in the background?
biggest bill
12/9/2017
11:08
Still not worth a punt here. Early birds are being flushed.Not until the whopping cash call. It will come, probably after a positive RNS about one of the products, and a small spike in the price.Maybe then it's worth gambling your beer money on.3p- I think.
backtogo
05/9/2017
07:24
Sorry for O/T again guys but take a look at OPTI. They've just struck a deal with Tata Chemicals!
parob
01/9/2017
09:24
IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Only other similar drug Benlysta was bought out from HGSi by GSK in 2012 for $3.6 billion for 50% stake valuing Benlysta around $7 billion (and IMM's Lupuzor appears to be safer and more efficaceous than Benlysta). $7 billion buyout of IMM gives £39.70 share price against current 49p, or 80 bagger !!! Potential blockbuster Lupuzor has 'Fast Track' and 'SPA' status from US FDA, so could market launched in 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://www.youtube.com/watch?v=M5Af_uSSXTM
top tips
28/8/2017
17:16
Opti & n4p are my banks over the next 12 to 18 months. Both have yet to spread there wings
zebbo
24/8/2017
12:09
Another 127K for me.OPTI still rising guys...
parob
23/8/2017
19:29
If this drops to 5.75p on the offer I'm having a load more.Worth taking a gander at OPTI folks.
parob
23/8/2017
14:36
I see that Flexton has been outed as the troll Slopjockey who posts on lse about n4p. Both Flexton and Slopjockey have said that they would stop posting comments on n4p but just can't help himself. Obviously someone with a personal grudge about n4p.
square root
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171018 02:06:55